Site Search
Professionals 471 results
Capabilities 83 results
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
Government Program Fraud, False Claims Act & Qui Tam Litigation
Investigations and litigation involving alleged fraud against the government pose a significant and growing threat to organizations and individuals across all industries that engage directly or indirectly in business with federal, state, and/or local governments. The government makes aggressive use of its extensive criminal and civil investigatory powers to root out alleged fraud and abuse implicating government funds, including one of its most powerful civil enforcement tools—the federal False Claims Act (FCA)—and similar state false claims statutes.
Experience 209 results
Experience
|April 6, 2026
MLBPI’s Licensing Fight Ends in Victory and Settlement with DraftKings
Winston is representing MLB Players Inc. (MLBPI), which serves as the exclusive group licensing representative for all MLB (major league baseball) players. MLBPI sued several online sportsbook and mobile-betting platforms, including DraftKings, over their use of hundreds of MLB player images and likenesses without MLBPI’s consent.
Experience
|April 2, 2026
Business Combination and Secured Financing of Keo World and Maha Capital AB
Served as legal counsel to KEO World, Inc., a Miami-based fintech platform specializing in embedded credit and B2B digital payments, in connection with its business combination with Maha Capital AB, a publicly listed investment company on Nasdaq Stockholm. The transaction, which closed on April 2, 2026, was structured as a reverse triangular merger through which KEO World became a wholly owned subsidiary of Maha, with KEO World's parent entity receiving approximately 141 million newly issued Maha shares and nearly 49.2 million earn-out warrants as consideration. In connection with the closing, Maha also executed two directed capital raises totaling USD 27 million at SEK 16 per share and announced a planned third raise of USD 8 million ahead of a contemplated dual listing on a U.S. national securities exchange. Based on publicly available disclosures, the combined transaction has been valued at approximately USD 680 million.
Experience
|March 30, 2026
Winston & Strawn LLP Paris advised NextStage AM on its investment in Evoluderm, a leading French player in the hygiene and beauty sector. This growth capital transaction, led by NextStage AM as a minority investor, will provide Nathalie and Gabriel Aiach – founders and majority shareholders with over 20 years’ expertise in the cosmetics sector – with the means to accelerate their ambition: to make Evoluderm an iconic brand, ranking among the world leaders in accessible, high-quality beauty. Founded in 2004, Evoluderm has established itself over the last five years as a benchmark in the health and beauty sector, distributed in over 100 countries. The brand has thus experienced remarkable growth, with turnover tripling over the last three years to reach nearly €40 million in 2025. With the support of NextStage AM, Evoluderm is embarking on an ambitious development plan to consolidate its position as a market leader.
Insights & News 5,185 results
In the Media
|April 24, 2026
|1 Min Read
Aimee Fagan Joins Winston in Dallas
Winston & Strawn recently announced that Aimee Fagan has joined the firm’s Dallas office as a partner in the Litigation Department and a member of the Intellectual Property Practice. Aimee is a first-chair trial lawyer whose practice focuses on intellectual property and complex commercial litigation. She represents clients in high-stakes disputes, with significant experience in technology and IP matters, particularly within the energy sector, as well as across the technology, financial services, private equity, medical, and retail industries.
In the Media
|April 24, 2026
|1 Min Read
The American Lawyer Spotlights Winston’s Momentum with Six Partner Additions
Winston was featured in The American Lawyer following the firm’s addition of six lateral partners across Chicago, New York, Washington, D.C., and Dallas in April, further strengthening key practices including leveraged finance, investigations, intellectual property, and appellate litigation.
Press Release
|April 20, 2026
|1 Min Read
Winston Strengthens Texas Intellectual Property Practice with Aimee Fagan
Dallas, TX – April 20, 2026 – Winston & Strawn LLP announced today that Aimee Fagan has joined the firm as a partner in the Litigation Department and the Intellectual Property Practice in Dallas.Aimee is a first-chair trial lawyer whose practice focuses on intellectual property and complex commercial litigation. She represents clients in high-stakes disputes, with significant experience in technology and IP matters, particularly within the energy sector, as well as across the technology, financial services, private equity, medical, and retail industries.“I’m excited to join such a dynamic team that is highly regarded for both its substantial trial capabilities and its deep experience managing complex IP and commercial disputes,” Aimee said. “I look forward to leveraging my experience and collaborating across the Dallas and Houston offices to deliver the high-caliber client service for which Winston is known.”Aimee’s patent and trade secret litigation experience, particularly in the energy sector, further enhances the firm’s established strengths and platform in IP litigation across Texas.
Other Results 125 results
Site Content
Site Content
The Jones Act, as used in the world of shipping is a law that reserves the transportation of goods between two points in the United States to qualified U.S.-flag vessels. This coastwise reservation law is named after its chief sponsor, Senator Wesley L. Jones. Similar laws apply to the transportation of passengers and reserve towing, dredging, and fishing in U.S. waters to qualified U.S.-flag vessels. Such vessels must be U.S. citizen-owned, U.S. citizen-crewed, U.S.-registered, and U.S.-built. Another law, also called the “Jones Act,” relates to merchant mariner injury recoveries.
Site Content
What Is the Securities Act of 1933?
The Securities Act of 1933 (as amended, the “Securities Act”) was passed to ensure that investors have financial and other important information about securities that are being sold publicly. It also bans the use of fraud, deceit, and misrepresentation in the sales of securities. The Securities Act, which is also referred to as the “truth in securities” law, is part of a legislative effort to govern and oversee the securities industry.